- Home
- CUPR vs MAIA Comparison
CUPR vs MAIA Comparison
Compare CUPR & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUPR
- MAIA
- Stock Information
- Founded
- CUPR 2019
- MAIA 2018
- Country
- CUPR Singapore
- MAIA United States
- Employees
- CUPR N/A
- MAIA N/A
- Industry
- CUPR
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- CUPR
- MAIA Health Care
- Exchange
- CUPR NYSE
- MAIA Nasdaq
- Market Cap
- CUPR 43.2M
- MAIA 46.7M
- IPO Year
- CUPR 2025
- MAIA 2022
- Fundamental
- Price
- CUPR $7.30
- MAIA $1.88
- Analyst Decision
- CUPR
- MAIA
- Analyst Count
- CUPR 0
- MAIA 0
- Target Price
- CUPR N/A
- MAIA N/A
- AVG Volume (30 Days)
- CUPR 300.3K
- MAIA 529.1K
- Earning Date
- CUPR 01-01-0001
- MAIA 08-08-2025
- Dividend Yield
- CUPR N/A
- MAIA N/A
- EPS Growth
- CUPR N/A
- MAIA N/A
- EPS
- CUPR N/A
- MAIA N/A
- Revenue
- CUPR $35,406.00
- MAIA N/A
- Revenue This Year
- CUPR N/A
- MAIA N/A
- Revenue Next Year
- CUPR N/A
- MAIA N/A
- P/E Ratio
- CUPR N/A
- MAIA N/A
- Revenue Growth
- CUPR N/A
- MAIA N/A
- 52 Week Low
- CUPR $3.51
- MAIA $1.40
- 52 Week High
- CUPR $7.46
- MAIA $4.24
- Technical
- Relative Strength Index (RSI)
- CUPR N/A
- MAIA 56.41
- Support Level
- CUPR N/A
- MAIA $1.80
- Resistance Level
- CUPR N/A
- MAIA $2.15
- Average True Range (ATR)
- CUPR 0.00
- MAIA 0.13
- MACD
- CUPR 0.00
- MAIA 0.02
- Stochastic Oscillator
- CUPR 0.00
- MAIA 60.00
About CUPR CUPRINA HOLDINGS (CAYMAN) LIMITED
Cuprina Holdings (Cayman) Ltd is a biomedical and biotechnology company that is dedicated to the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. It manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.